3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Promyelocytic, Acute
11
Leukemia, Myeloid, Acute
4
Leukemia
3
Myelodysplastic Syndromes
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Neutropenia
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Hematologic Neoplasms
1
Frailty
1
Breast Cancer Female
1
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
12
Rituximab
10
Gemcitabine
9
Paclitaxel
8
Bendamustine Hydrochloride
8
Lenalidomide
7
Decitabine
7
Cytarabine
7
Carboplatin
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Bevacizumab
4
Antilymphocyte Serum
4
venetoclax
3
pomalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
Tretinoin
×
Clear all
NCT02717884
2018-10-18
TRANSATRA
University Hospital Freiburg
Phase 1/2
Unknown
60 enrolled